These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 28115277)

  • 1. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
    Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
    BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
    Ebraheem M; Kumar SK; Dispenzieri A; Jevremovic D; Buadi FK; Dingli D; Cook J; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Binder M; Lin Y; Go RS; Siddiqui MA; Kyle RA; Rajkumar SV; Gonsalves WI; Gertz MA
    Transplant Cell Ther; 2022 Nov; 28(11):760.e1-760.e5. PubMed ID: 35940527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
    Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
    J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
    Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
    Hu B; Thall P; Milton DR; Sasaki K; Bashir Q; Shah N; Patel K; Popat U; Hosing C; Nieto Y; Lin P; Delgado R; Jorgensen J; Manasanch E; Weber D; Thomas S; Orlowski RZ; Champlin R; Qazilbash MH
    Leuk Lymphoma; 2019 Feb; 60(2):442-452. PubMed ID: 30032678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
    J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
    Guman T; Sykora J
    Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
    Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
    [No Abstract]   [Full Text] [Related]  

  • 14. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
    Pasquini MC; Wallace PK; Logan B; Kaur M; Tario JD; Howard A; Zhang Y; Brunstein C; Efebera Y; Geller N; Giralt S; Hari P; Horowitz MM; Koreth J; Krishnan A; Landau H; Somlo G; Shah N; Stadtmauer E; Vogl DT; Vesole DH; McCarthy PL; Hahn T
    J Clin Oncol; 2024 Aug; 42(23):2757-2768. PubMed ID: 38701390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
    de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG
    J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
    Belotti A; Ribolla R; Cancelli V; Villanacci A; Angelini V; Chiarini M; Giustini V; Facchetti GV; Roccaro AM; Ferrari S; Peli A; Bottelli C; Cattaneo C; Crippa C; Micilotta M; Frittoli B; Grazioli L; Rossi G; Tucci A
    Cancer Med; 2021 Sep; 10(17):5859-5865. PubMed ID: 34263564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
    Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
    J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
    Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792
    [No Abstract]   [Full Text] [Related]  

  • 19. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades.
    Pasvolsky O; Marcoux C; Dai J; Milton DR; Tanner MR; Syed N; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Aljawai Y; Lee HC; Gaballa MR; Patel KK; Kebriaei P; Thomas SK; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2024 Aug; 30(8):772.e1-772.e11. PubMed ID: 38852784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
    Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Shadman M; Maloney DG; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):380-385. PubMed ID: 26348890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.